Fig. 2: The presence of circulating LRPAP1_7-30V-specific CD4⁺ T cells after one round of in vitro expansion with the TEIPP24 peptide.

TEIPP24 peptide-expanded cells were stimulated with non-loaded (medium) or TEIPP24-peptide-loaded autologous monocytes in the presence of brefeldin A. Subsequently, the cells were stained with antibodies against CD3, CD4, CD8, CD137, CD154, GM-CSF, IFNγ, TNFα, IL2 and CCL4. Cells were gated as described in fig. S4. a, b Percentage of LRPAP1_7-30V-specific CD4⁺ T cells in the PBMC at baseline (BL) and after 1, 2 and 3 vaccinations (V1-V3) is provided for 13 patients in which we could detect LRPAP1_7-30V-specific CD4⁺ T cells across (a) all and (b) the different cohorts. c Percentage of single (SP; yellow), double (DP; green), triple (TP; orange), quadruple (Q4P; blue), and quintuple (Q5P; purple) cytokine-positive LRPAP1_7-30V–specific CD4⁺ T cells is depicted at baseline (BL) and after 1, 2 and 3 vaccinations (v1-v3) with the TEIPP24 vaccine for 13 patients in which we could detect LRPAP1_7-30V-specific CD4⁺ T cells. P-values versus baseline are indicated at the side of the bar. d Number of patients displaying either no (none; white), only a CD4⁺ T cell (red), only a CD8⁺ T cell (blue), or a combined (both) CD4⁺ and CD8⁺ T-cell response (green) after vaccination. e Percentage of LRPAP1_{21-30S_V}-specific CD8⁺ T cells in the PBMC of the 21 patients tested for the reactivity of both CD4 and CD8 T cells, at baseline (BL) and after 1, 2 and 3 vaccinations (v1-v3) for patients without and with a detectable LRPAP1-specific CD4⁺ T-cell response (CD4 non-responders (left) and CD4 responders (right)). Data are represented as scatter plots with bars indicating mean and dots representing individual data points (a, b, e) or as stacked bars (c, d). Statistical analysis by unpaired non-parametric Kruskal-Wallis with Dunn’s multiple comparisons test (a, b, c, e). Source data are provided as a Source Data file.